

# Global Cutaneous and Systemic Leishmaniasis Drugs Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/G87AF193523EN.html>

Date: March 2023

Pages: 86

Price: US\$ 3,660.00 (Single User License)

ID: G87AF193523EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Cutaneous and Systemic Leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.

LPI (LP Information)' newest research report, the “Cutaneous and Systemic Leishmaniasis Drugs Industry Forecast” looks at past sales and reviews total world Cutaneous and Systemic Leishmaniasis Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Cutaneous and Systemic Leishmaniasis Drugs sales for 2023 through 2029. With Cutaneous and Systemic Leishmaniasis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Cutaneous and Systemic Leishmaniasis Drugs industry.

This Insight Report provides a comprehensive analysis of the global Cutaneous and Systemic Leishmaniasis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cutaneous and Systemic Leishmaniasis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cutaneous and Systemic Leishmaniasis Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cutaneous and Systemic Leishmaniasis Drugs and

breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cutaneous and Systemic Leishmaniasis Drugs.

The global Cutaneous and Systemic Leishmaniasis Drugs market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Cutaneous and Systemic Leishmaniasis Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Cutaneous and Systemic Leishmaniasis Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Cutaneous and Systemic Leishmaniasis Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Cutaneous and Systemic Leishmaniasis Drugs players cover GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Novartis, Sanofi, Bristol-Myers Squibb, Profounda, Knight Therapeutics and Albert David, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Cutaneous and Systemic Leishmaniasis Drugs market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Pentavalent Antimonials

Antifungal Drugs

## Anti-Leishmanial/Antimicrobial Drugs

### Segmentation by application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

### This report also splits the market by region:

#### Americas

United States

Canada

Mexico

Brazil

#### APAC

China

Japan

Korea

Southeast Asia

India

Australia

#### Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

GlaxoSmithKline

Gilead Sciences

Johnson & Johnson

Novartis

Sanofi

Bristol-Myers Squibb

Profunda

Knight Therapeutics

Albert David

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Cutaneous and Systemic Leishmaniasis Drugs Market Size 2018-2029
  - 2.1.2 Cutaneous and Systemic Leishmaniasis Drugs Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Cutaneous and Systemic Leishmaniasis Drugs Segment by Type
  - 2.2.1 Pentavalent Antimonials
  - 2.2.2 Antifungal Drugs
  - 2.2.3 Anti-Leishmanial/Antimicrobial Drugs
- 2.3 Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type
  - 2.3.1 Cutaneous and Systemic Leishmaniasis Drugs Market Size CAGR by Type (2018 VS 2022 VS 2029)
  - 2.3.2 Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type (2018-2023)
- 2.4 Cutaneous and Systemic Leishmaniasis Drugs Segment by Application
  - 2.4.1 Hospital Pharmacies
  - 2.4.2 Retail Pharmacies
  - 2.4.3 Online Pharmacies
- 2.5 Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application
  - 2.5.1 Cutaneous and Systemic Leishmaniasis Drugs Market Size CAGR by Application (2018 VS 2022 VS 2029)
  - 2.5.2 Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application (2018-2023)

### 3 CUTANEOUS AND SYSTEMIC LEISHMANIASIS DRUGS MARKET SIZE BY

## **PLAYER**

### 3.1 Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Players

3.1.1 Global Cutaneous and Systemic Leishmaniasis Drugs Revenue by Players (2018-2023)

3.1.2 Global Cutaneous and Systemic Leishmaniasis Drugs Revenue Market Share by Players (2018-2023)

### 3.2 Global Cutaneous and Systemic Leishmaniasis Drugs Key Players Head office and Products Offered

### 3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

### 3.4 New Products and Potential Entrants

### 3.5 Mergers & Acquisitions, Expansion

## **4 CUTANEOUS AND SYSTEMIC LEISHMANIASIS DRUGS BY REGIONS**

### 4.1 Cutaneous and Systemic Leishmaniasis Drugs Market Size by Regions (2018-2023)

4.2 Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth (2018-2023)

4.3 APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth (2018-2023)

4.4 Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth (2018-2023)

4.5 Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth (2018-2023)

## **5 AMERICAS**

5.1 Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size by Country (2018-2023)

5.2 Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023)

5.3 Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

## 5.7 Brazil

## **6 APAC**

6.1 APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size by Region (2018-2023)

6.2 APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023)

6.3 APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

## **7 EUROPE**

7.1 Europe Cutaneous and Systemic Leishmaniasis Drugs by Country (2018-2023)

7.2 Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023)

7.3 Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs by Region (2018-2023)

8.2 Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023)

8.3 Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023)

8.4 Egypt



8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 GLOBAL CUTANEOUS AND SYSTEMIC LEISHMANIASIS DRUGS MARKET FORECAST**

10.1 Global Cutaneous and Systemic Leishmaniasis Drugs Forecast by Regions (2024-2029)

10.1.1 Global Cutaneous and Systemic Leishmaniasis Drugs Forecast by Regions (2024-2029)

10.1.2 Americas Cutaneous and Systemic Leishmaniasis Drugs Forecast

10.1.3 APAC Cutaneous and Systemic Leishmaniasis Drugs Forecast

10.1.4 Europe Cutaneous and Systemic Leishmaniasis Drugs Forecast

10.1.5 Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Forecast

10.2 Americas Cutaneous and Systemic Leishmaniasis Drugs Forecast by Country (2024-2029)

10.2.1 United States Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.2.2 Canada Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.2.3 Mexico Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.2.4 Brazil Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.3 APAC Cutaneous and Systemic Leishmaniasis Drugs Forecast by Region (2024-2029)

10.3.1 China Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.3.2 Japan Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.3.3 Korea Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.3.4 Southeast Asia Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.3.5 India Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.3.6 Australia Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

10.4 Europe Cutaneous and Systemic Leishmaniasis Drugs Forecast by Country (2024-2029)

10.4.1 Germany Cutaneous and Systemic Leishmaniasis Drugs Market Forecast

- 10.4.2 France Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
- 10.4.3 UK Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
- 10.4.4 Italy Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
- 10.4.5 Russia Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
- 10.5 Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Forecast by Region (2024-2029)
  - 10.5.1 Egypt Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
  - 10.5.2 South Africa Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
  - 10.5.3 Israel Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
  - 10.5.4 Turkey Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
  - 10.5.5 GCC Countries Cutaneous and Systemic Leishmaniasis Drugs Market Forecast
- 10.6 Global Cutaneous and Systemic Leishmaniasis Drugs Forecast by Type (2024-2029)
- 10.7 Global Cutaneous and Systemic Leishmaniasis Drugs Forecast by Application (2024-2029)

## **11 KEY PLAYERS ANALYSIS**

### 11.1 GlaxoSmithKline

- 11.1.1 GlaxoSmithKline Company Information
- 11.1.2 GlaxoSmithKline Cutaneous and Systemic Leishmaniasis Drugs Product Offered
- 11.1.3 GlaxoSmithKline Cutaneous and Systemic Leishmaniasis Drugs Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 GlaxoSmithKline Main Business Overview
- 11.1.5 GlaxoSmithKline Latest Developments

### 11.2 Gilead Sciences

- 11.2.1 Gilead Sciences Company Information
- 11.2.2 Gilead Sciences Cutaneous and Systemic Leishmaniasis Drugs Product Offered
- 11.2.3 Gilead Sciences Cutaneous and Systemic Leishmaniasis Drugs Revenue, Gross Margin and Market Share (2018-2023)
- 11.2.4 Gilead Sciences Main Business Overview
- 11.2.5 Gilead Sciences Latest Developments

### 11.3 Johnson & Johnson

- 11.3.1 Johnson & Johnson Company Information
- 11.3.2 Johnson & Johnson Cutaneous and Systemic Leishmaniasis Drugs Product Offered
- 11.3.3 Johnson & Johnson Cutaneous and Systemic Leishmaniasis Drugs Revenue,

## Gross Margin and Market Share (2018-2023)

11.3.4 Johnson & Johnson Main Business Overview

11.3.5 Johnson & Johnson Latest Developments

## 11.4 Novartis

11.4.1 Novartis Company Information

11.4.2 Novartis Cutaneous and Systemic Leishmaniasis Drugs Product Offered

11.4.3 Novartis Cutaneous and Systemic Leishmaniasis Drugs Revenue, Gross

## Margin and Market Share (2018-2023)

11.4.4 Novartis Main Business Overview

11.4.5 Novartis Latest Developments

## 11.5 Sanofi

11.5.1 Sanofi Company Information

11.5.2 Sanofi Cutaneous and Systemic Leishmaniasis Drugs Product Offered

11.5.3 Sanofi Cutaneous and Systemic Leishmaniasis Drugs Revenue, Gross Margin and Market Share (2018-2023)

11.5.4 Sanofi Main Business Overview

11.5.5 Sanofi Latest Developments

## 11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Information

11.6.2 Bristol-Myers Squibb Cutaneous and Systemic Leishmaniasis Drugs Product Offered

11.6.3 Bristol-Myers Squibb Cutaneous and Systemic Leishmaniasis Drugs Revenue, Gross Margin and Market Share (2018-2023)

11.6.4 Bristol-Myers Squibb Main Business Overview

11.6.5 Bristol-Myers Squibb Latest Developments

## 11.7 Profounda

11.7.1 Profounda Company Information

11.7.2 Profounda Cutaneous and Systemic Leishmaniasis Drugs Product Offered

11.7.3 Profounda Cutaneous and Systemic Leishmaniasis Drugs Revenue, Gross Margin and Market Share (2018-2023)

11.7.4 Profounda Main Business Overview

11.7.5 Profounda Latest Developments

## 11.8 Knight Therapeutics

11.8.1 Knight Therapeutics Company Information

11.8.2 Knight Therapeutics Cutaneous and Systemic Leishmaniasis Drugs Product Offered

11.8.3 Knight Therapeutics Cutaneous and Systemic Leishmaniasis Drugs Revenue, Gross Margin and Market Share (2018-2023)

11.8.4 Knight Therapeutics Main Business Overview

11.8.5 Knight Therapeutics Latest Developments

11.9 Albert David

11.9.1 Albert David Company Information

11.9.2 Albert David Cutaneous and Systemic Leishmaniasis Drugs Product Offered

11.9.3 Albert David Cutaneous and Systemic Leishmaniasis Drugs Revenue, Gross Margin and Market Share (2018-2023)

11.9.4 Albert David Main Business Overview

11.9.5 Albert David Latest Developments

## **12 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Cutaneous and Systemic Leishmaniasis Drugs Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Pentavalent Antimonials

Table 3. Major Players of Antifungal Drugs

Table 4. Major Players of Anti-Leishmanial/Antimicrobial Drugs

Table 5. Cutaneous and Systemic Leishmaniasis Drugs Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 6. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023) & (\$ Millions)

Table 7. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type (2018-2023)

Table 8. Cutaneous and Systemic Leishmaniasis Drugs Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 9. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023) & (\$ Millions)

Table 10. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application (2018-2023)

Table 11. Global Cutaneous and Systemic Leishmaniasis Drugs Revenue by Players (2018-2023) & (\$ Millions)

Table 12. Global Cutaneous and Systemic Leishmaniasis Drugs Revenue Market Share by Player (2018-2023)

Table 13. Cutaneous and Systemic Leishmaniasis Drugs Key Players Head office and Products Offered

Table 14. Cutaneous and Systemic Leishmaniasis Drugs Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size by Regions 2018-2023 & (\$ Millions)

Table 18. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Regions (2018-2023)

Table 19. Global Cutaneous and Systemic Leishmaniasis Drugs Revenue by Country/Region (2018-2023) & (\$ millions)

Table 20. Global Cutaneous and Systemic Leishmaniasis Drugs Revenue Market Share by Country/Region (2018-2023)

Table 21. Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size by Country (2018-2023) & (\$ Millions)

Table 22. Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Country (2018-2023)

Table 23. Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023) & (\$ Millions)

Table 24. Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type (2018-2023)

Table 25. Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023) & (\$ Millions)

Table 26. Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application (2018-2023)

Table 27. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size by Region (2018-2023) & (\$ Millions)

Table 28. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Region (2018-2023)

Table 29. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023) & (\$ Millions)

Table 30. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type (2018-2023)

Table 31. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023) & (\$ Millions)

Table 32. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application (2018-2023)

Table 33. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size by Country (2018-2023) & (\$ Millions)

Table 34. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Country (2018-2023)

Table 35. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023) & (\$ Millions)

Table 36. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type (2018-2023)

Table 37. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023) & (\$ Millions)

Table 38. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application (2018-2023)

Table 39. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size by Region (2018-2023) & (\$ Millions)

Table 40. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market

## Size Market Share by Region (2018-2023)

Table 41. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size by Type (2018-2023) & (\$ Millions)

Table 42. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type (2018-2023)

Table 43. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size by Application (2018-2023) & (\$ Millions)

Table 44. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application (2018-2023)

Table 45. Key Market Drivers & Growth Opportunities of Cutaneous and Systemic Leishmaniasis Drugs

Table 46. Key Market Challenges & Risks of Cutaneous and Systemic Leishmaniasis Drugs

Table 47. Key Industry Trends of Cutaneous and Systemic Leishmaniasis Drugs

Table 48. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 49. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share Forecast by Regions (2024-2029)

Table 50. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 51. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 52. GlaxoSmithKline Details, Company Type, Cutaneous and Systemic Leishmaniasis Drugs Area Served and Its Competitors

Table 53. GlaxoSmithKline Cutaneous and Systemic Leishmaniasis Drugs Product Offered

Table 54. GlaxoSmithKline Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 55. GlaxoSmithKline Main Business

Table 56. GlaxoSmithKline Latest Developments

Table 57. Gilead Sciences Details, Company Type, Cutaneous and Systemic Leishmaniasis Drugs Area Served and Its Competitors

Table 58. Gilead Sciences Cutaneous and Systemic Leishmaniasis Drugs Product Offered

Table 59. Gilead Sciences Main Business

Table 60. Gilead Sciences Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 61. Gilead Sciences Latest Developments

Table 62. Johnson & Johnson Details, Company Type, Cutaneous and Systemic

Leishmaniasis Drugs Area Served and Its Competitors

Table 63. Johnson & Johnson Cutaneous and Systemic Leishmaniasis Drugs Product Offered

Table 64. Johnson & Johnson Main Business

Table 65. Johnson & Johnson Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 66. Johnson & Johnson Latest Developments

Table 67. Novartis Details, Company Type, Cutaneous and Systemic Leishmaniasis Drugs Area Served and Its Competitors

Table 68. Novartis Cutaneous and Systemic Leishmaniasis Drugs Product Offered

Table 69. Novartis Main Business

Table 70. Novartis Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 71. Novartis Latest Developments

Table 72. Sanofi Details, Company Type, Cutaneous and Systemic Leishmaniasis Drugs Area Served and Its Competitors

Table 73. Sanofi Cutaneous and Systemic Leishmaniasis Drugs Product Offered

Table 74. Sanofi Main Business

Table 75. Sanofi Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 76. Sanofi Latest Developments

Table 77. Bristol-Myers Squibb Details, Company Type, Cutaneous and Systemic Leishmaniasis Drugs Area Served and Its Competitors

Table 78. Bristol-Myers Squibb Cutaneous and Systemic Leishmaniasis Drugs Product Offered

Table 79. Bristol-Myers Squibb Main Business

Table 80. Bristol-Myers Squibb Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 81. Bristol-Myers Squibb Latest Developments

Table 82. Profunda Details, Company Type, Cutaneous and Systemic Leishmaniasis Drugs Area Served and Its Competitors

Table 83. Profunda Cutaneous and Systemic Leishmaniasis Drugs Product Offered

Table 84. Profunda Main Business

Table 85. Profunda Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 86. Profunda Latest Developments

Table 87. Knight Therapeutics Details, Company Type, Cutaneous and Systemic Leishmaniasis Drugs Area Served and Its Competitors

Table 88. Knight Therapeutics Cutaneous and Systemic Leishmaniasis Drugs Product



Offered

Table 89. Knight Therapeutics Main Business

Table 90. Knight Therapeutics Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 91. Knight Therapeutics Latest Developments

Table 92. Albert David Details, Company Type, Cutaneous and Systemic Leishmaniasis Drugs Area Served and Its Competitors

Table 93. Albert David Cutaneous and Systemic Leishmaniasis Drugs Product Offered

Table 94. Albert David Main Business

Table 95. Albert David Cutaneous and Systemic Leishmaniasis Drugs Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 96. Albert David Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Cutaneous and Systemic Leishmaniasis Drugs Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth Rate 2018-2029 (\$ Millions)

Figure 6. Cutaneous and Systemic Leishmaniasis Drugs Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Figure 7. Cutaneous and Systemic Leishmaniasis Drugs Sales Market Share by Country/Region (2022)

Figure 8. Cutaneous and Systemic Leishmaniasis Drugs Sales Market Share by Country/Region (2018, 2022 & 2029)

Figure 9. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type in 2022

Figure 10. Cutaneous and Systemic Leishmaniasis Drugs in Hospital Pharmacies

Figure 11. Global Cutaneous and Systemic Leishmaniasis Drugs Market: Hospital Pharmacies (2018-2023) & (\$ Millions)

Figure 12. Cutaneous and Systemic Leishmaniasis Drugs in Retail Pharmacies

Figure 13. Global Cutaneous and Systemic Leishmaniasis Drugs Market: Retail Pharmacies (2018-2023) & (\$ Millions)

Figure 14. Cutaneous and Systemic Leishmaniasis Drugs in Online Pharmacies

Figure 15. Global Cutaneous and Systemic Leishmaniasis Drugs Market: Online Pharmacies (2018-2023) & (\$ Millions)

Figure 16. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application in 2022

Figure 17. Global Cutaneous and Systemic Leishmaniasis Drugs Revenue Market Share by Player in 2022

Figure 18. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Regions (2018-2023)

Figure 19. Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size 2018-2023 (\$ Millions)

Figure 20. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size 2018-2023 (\$ Millions)

Figure 21. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size 2018-2023 (\$ Millions)

Figure 22. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size 2018-2023 (\$ Millions)

Figure 23. Americas Cutaneous and Systemic Leishmaniasis Drugs Value Market Share by Country in 2022

Figure 24. United States Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Region in 2022

Figure 29. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type in 2022

Figure 30. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application in 2022

Figure 31. China Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Country in 2022

Figure 38. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type (2018-2023)

Figure 39. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application (2018-2023)

Figure 40. Germany Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 41. France Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth

2018-2023 (\$ Millions)

Figure 42. UK Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth

2018-2023 (\$ Millions)

Figure 43. Italy Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth

2018-2023 (\$ Millions)

Figure 44. Russia Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth

2018-2023 (\$ Millions)

Figure 45. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Region (2018-2023)

Figure 46. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Type (2018-2023)

Figure 47. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share by Application (2018-2023)

Figure 48. Egypt Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 49. South Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 50. Israel Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Turkey Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 52. GCC Country Cutaneous and Systemic Leishmaniasis Drugs Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Americas Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 54. APAC Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 55. Europe Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 56. Middle East & Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 57. United States Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 58. Canada Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 59. Mexico Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 60. Brazil Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 61. China Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 62. Japan Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 63. Korea Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 65. India Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 66. Australia Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 67. Germany Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 68. France Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 69. UK Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 70. Italy Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 71. Russia Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 72. Spain Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 75. Israel Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries Cutaneous and Systemic Leishmaniasis Drugs Market Size 2024-2029 (\$ Millions)

Figure 78. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share Forecast by Type (2024-2029)

Figure 79. Global Cutaneous and Systemic Leishmaniasis Drugs Market Size Market Share Forecast by Application (2024-2029)

## I would like to order

Product name: Global Cutaneous and Systemic Leishmaniasis Drugs Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/G87AF193523EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G87AF193523EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

